Results for "Werewolf Therapeutics"

Werewolf Therapeutics stock surged over 100% following the announcement of a merger agreement with Ambros Therapeutics and a concurrent oversubscribed $150 million private placement. This news significantly boosted investor confidence.

IES Holdings, BrightSpring Health Services, Fortis, and Linde all reported strong financial results, surpassing analyst expectations for both revenue and non-GAAP EPS, while Tenax Therapeutics also beat its GAAP EPS estimate.

Werewolf Therapeutics announced a GAAP EPS of -$0.20, beating analyst estimates by $0.14.